Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00300274 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 721
- Enrollment target
NCT00300274 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 721 participants.
The verdict
NCT00300274, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 721 participants
- Enrollment target
Study Summary
This trial was to examine the impact of everolimus and reduced dose of cyclosporine on efficacy and safety compared to mycophenolate mofetil and a standard dose of cyclosporine in heart transplant recipients.
Interventions
- DRUG everolimus
- DRUG cyclosporine
- DRUG mycophenolate mofetil
- DRUG corticosteroids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 721 participants |
| Start Date | 2006-01 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00300274
The ClinicalTrials.gov registry entry for NCT00300274 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 721 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which everolimus is the first listed.
NCT00300274 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00300274 about?
NCT00300274 is a clinical study titled "Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection". This trial was to examine the impact of everolimus and reduced dose of cyclosporine on efficacy and safety compared to mycophenolate mofetil and a standard dose of cyclosporine in heart transplant recipients.
What is the current status of trial NCT00300274?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 721 participants. The study started on 2006-01. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00300274?
The interventions under investigation include: everolimus (DRUG), cyclosporine (DRUG), mycophenolate mofetil (DRUG), corticosteroids (DRUG).
Who is sponsoring clinical trial NCT00300274?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.